CYCLOPHOSPHAMIDE, HEXAMETHYLMELAMINE, DOXORUBICIN, AND CISPLATIN (CHAD) AS 2ND-LINE CHEMOTHERAPY FOR OVARIAN ADENOCARCINOMA

  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (1-2) , 149-151
Abstract
Twenty women with recurrent ovarian adenocarcinoma received a monthly 4-drug combination of cyclophosphamide, hexamethylmelamine, doxorubicin and cisplatin as 2nd-line chemotherapy. There were no objective responses to this regimen. This is in contrast to the 49% response rate reported by Kane using these 4 drugs and the 63% response rate reported by Vogl using 3 of these drugs as 2nd-line chemotherapy. The differences in the 3 regimens are reviewed; reasons sufficient to account for the disparity in response rates could not be identified.